DoMore Diagnostics and Stavanger University Hospital to Collaborate on the Digital Biomarker Histotype Px® Colorectal to Personalize Cancer Treatment
OSLO - 19 October, 2023 - DoMore Diagnostics, a leader in deep learning precision diagnostics for digital pathology, announces a new collaboration with Stavanger University Hospital (SUH) aimed at improving personalized treatment for colorectal cancer patients.
Under the agreement, SUH will validate the Histotype Px® Colorectal* digital biomarker in patients from the Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer (ACROBATICC) study (1). Following this validation, SUH will test the clinical utility of Histotype Px Colorectal in a group of Norwegian colorectal cancer patients.
Colorectal cancer is the third most common type of cancer and the second leading cause of cancer related death. Patients in stage II and III undergo surgery to eradicate the cancer and adjuvant chemotherapy is commonly prescribed to reduce the risk of relapse. However it comes with significant side effects and only benefits a minority of patients. As such, there is a large medical need for biomarkers that can guide personalized treatment decisions. Histotype Px Colorectal aims to address these challenges by analyzing the unique histological features of each patient's tumor.
“We are excited to collaborate with DoMore Diagnostics to validate the biomarker in patients from our ACROBATICC study. We need new and better biomarkers for colorectal cancer to provide more precise and personalized care. With such a tool, we hope to optimize treatment strategies, minimize side effects, and ultimately improve the lives of patients affected with this challenging disease,” said Professor Kjetil Søreide MD PhD FRCS (Edin) FACS FEBS (hon), consultant surgeon at Stavanger University Hospital and Professor of Surgery at University of Bergen and Leader of the Gastrointenstinal Translational Research Unit, SUH. Dr Søreide also serves as Editor of the British Journal of Surgery.
"Partnering with renowned colorectal cancer experts and researchers at SUH to further validate Histotype Px in colorectal cancer patients is yet another important step towards making the test widely accessible to patients across Norway and worldwide," said Dr. Torbjørn Furuseth, CEO and Co-Founder of DoMore Diagnostics. "SUH is a frontrunner in colorectal cancer and digital pathology in Norway, and through our collaboration we aim to reach our common goal of providing personalized treatment and better care to colorectal cancer patients."
*Histotype Px Colorectal is CE-marked under IVDD. For Research Use only outside the EU.
(1) For more information, see: Søreide et al. (2016) Journal of Translational Medicine
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Histotype Px Colorectal
Histotype Px Colorectal is an advanced deep learning algorithm that analyzes digital histology slides, identifying patients who may or may not benefit from adjuvant chemotherapy. Data previously published in The Lancet and Lancet Oncology showed the test can accurately predict survival outcomes in colorectal cancer patients. The Histotype Px Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
Contact:
CEO and Co-Founder Torbjørn Furuseth, MD
tf@domorediagnostics.com